Patients
For patients, management of a rare disease can be all-consuming. At MBX Biosciences, we are dedicated to making meaningful improvements in patients’ lives by minimizing their daily burden.
Canvuparatide (MBX 2109) is currently in a pivotal Phase 3 clinical trial (NCT07699471), paving the way towards a new approach for patients and physicians alike.
Through our innovative research, discovery, and development of novel therapeutics, we aim to change the therapeutic landscape for those living with hypoparathyroidism, obesity and other rare or prevalent diseases.
We are continually working with patients and advocacy groups to learn about the challenges patients experience in their daily lives and how we can best support them from a therapeutic perspective and beyond.
For questions or interest in participating in our clinical trials, please email us.
Info@mbxbio.com